Recent News

• 03.23.2026 - HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
• 03.09.2026 - HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
• 03.06.2026 - Intended Retirement of Independent Non-executive Director and changes of composition of board committees

Recent Filings

• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.16.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.16.2026 - 3 Initial statement of beneficial ownership of securities
• 03.16.2026 - EX-99.1 EX-99.1
• 03.11.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.11.2026 - EX-99.1 EX-99.1
• 03.11.2026 - 3 Initial statement of beneficial ownership of securities
• 03.10.2026 - 3 Initial statement of beneficial ownership of securities
• 03.10.2026 - 3 Initial statement of beneficial ownership of securities
• 03.10.2026 - 3 Initial statement of beneficial ownership of securities